刺络联合吸入疗法防治小儿哮喘肺脾两虚型临床观察

摘要

目的:观察刺络联合吸入疗法治疗轻、中度慢性持续期或缓解期小儿支气管哮喘(肺脾两虚型)临床疗效.方法:采用随机、平行对照法将86例患儿分为观察组和对照组各43例,对照组吸入舒利迭(沙美特罗替卡松粉吸入剂)150μg,每次1吸,2次/d,治疗90天;观察组在对照组治疗的基础上针刺四缝、少商、耳尖放血,隔日1次,治疗90天.观察治疗后2组临床症状评分、哮喘控制测试(C-ACT)评分及免疫指标改善情况.结果:治疗组临床症状改善优于对照组(P<0.01);2组治疗后C-ACT评分均不同程度升高,治疗组30天、60天时间点C-ACT评分高于对照组(P<0.05),治疗组90天时间点C-ACT评分高于对照组(P<0.01);治疗组治疗后IgM水平与治疗前比较差异有统计学意义(P<0.05),与对照组治疗后比较差异有统计学意义(P<0.05).结论:针刺四缝、少商、耳尖放血联合吸入舒利迭能更有效地控制轻、中度小儿支气管哮喘发作,改善哮喘症状.%Objective:To observe clinical effects of blood-letting puncture jointed with anemopathy in treating the children with mild and moderate bronchial asthma(dual deficiency pattern of lung-spleen) at chronic persistent or remission stage. Methods:By adopting randomized, parallel control study method, 86 children were allocated to the observation group and the control group, 43 cases each group, the control group inhaled seretide, 150 μg, inhaling once each time, treated for 90 days; the observation group accepted needling and blood letting of SiFeng (EX-UE10), ShaoShang (LU11) and ErJian (EX-HN6), once every two days, for 90 days. Clinical symptoms scales, children asthma control test (C-ACT) scales and the improvements of immune indexes of both groups were observed after treating in both groups. Results:The treatment group was superior to the control group in the improvements of clinical symptoms (P<0.01);C-ACT scales of both groups raised in different degrees, the treatment group was higher than the control group in C-ACT scales at the time of 30 days and 60 days(P<0.05), the treatment group was higher than the control group in C-ACT scales at the time of 90 days significantly (P<0.01);the difference had statistical meaning in the comparisons of IgM levels between before and after treating in the treatment group (P<0.05), the difference presented statistical meaning when the treatment group was compared with the control group after treating (P<0.05). Conclusion:Needling and blood letting of SiFeng, ShaoShang and ErJian jointed with inhalation of sere-tide could effectively control the attack of mild and moderate bronchial asthma in children and improve the symp-toms of asthma.